This is probably due to the fact that while committed progenitor cells and mature myeloid cells are very sensitive to BCR::ABL1 inhibition by TKIs, this is not the case in quiescent CML stem cells, hereby leaving this population as a disease reservoir [26]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.